DIAGNOSTIC GENETICS and GENOMICS

Gail H. Vance, M.D.Gail H. Vance Photo

Sutphin Professor of Cancer Genetics
Professor, Medical and Molecular Genetics
Professor, Pathology and Laboratory Medicine
Director, IU Genetic Testing Laboratories
Director, IU Division of Diagnostic Genomics
Director, IU Cytogenetic Laboratories
Director, Indiana Familial Cancer Program
Associate Director, IU Vector Production Facility

Professional Address: Indiana University School of Medicine, Department of Medical & Molecular Genetics, 635 Barnhill Drive, MS 350E, Indianapolis, IN 46202

Office Phone: 317-278-0172

Fax: 317-278-1616

E-mail: ghvance@iu.edu

Licensure:

Indiana, #0103602

Board Certifications:

Clinical Pathology, American Board of Pathology, 1989

Pediatrics, American Board of Pediatrics, 1990

Clinical Genetics and Cytogenetics, American Board of Medical Genetics, 1993, 2002, 2011

Areas of Specialization:

Cytogenetics/Cytogenomics

Familial Cancer

Cancer Cytogenetics

Research Interests:

HER2 Amplification in Breast Cancer

Cancer Cytogenetics

Federal Regulatory Affairs

Education:

M.D. 1980, College of Human Medicine, Michigan State University, East Lansing, Michigan

1980-81, Intern, Lab Medicine and Pathology, William Beaumont Hospital, Royal Oak, Michigan

1981-83, 86-87, Pediatric Resident, University of Minnesota, Minneapolis, Minnesota

1983-86, Lab Medicine and Pathology Resident, University of Minnesota, Minneapolis, Minnesota

Selected Articles:

Virts EL, Jankowska A, MacKay C, Glaas MF, Wiek C, Kelich SL, Lottmann N, Kennedy FM, Marchal C, Lehren E, Scharf R, Dufour C, Lanciotti M, Farruggi P, Santoro A, Savasan S, Scheckenbach K, Schipper J, Wagenmann M, Lewis T, Leffak M, Farlow JL, Foroud TM, Honisch E, Niederacher D, Chakraborty SC, Vance GH, Pruss D, Timms KM, Lanchbury JS, Alpi AF, Hanenberg H. Alu-Ymediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia. Human Molecular Genetics, 2015.  In Press.

Schneider BP, Li L, Radovich M, Shen F, Miller C, Flockhart DA, Jiang G, Vance GH, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O’Neill A, Smith ML, Railey E, White C, Patridge A, Sparano JA, Davidson NE, Foroud T, Sledge GW.  Genomic predictors for taxane- induced peripheral neuropathy. Clinical Cancer Research, 2015.  In press.

Khawaja MR, Perkins SM, Schwartz JE, Robertson MJ, Kiel PJ, Sayar H, Cox EA, Vance GH, Farag SS, Cripe LD, Nelson RP. Cyclophosphamide/Fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.  Am J Hematology 2015; 90(2):97-99.

Levy KD, Pratt VM, Skaar TC, Vance GH, Flockhart DA. FDA’s draft guidance on Laboratory-Developed Tests increases clinical and economic risk to adoption of pharmacogenetic testing. J. Clin Pharm 2015; 55(7), 725-727.

Pratt V, Beyer B, Koller D, Skaar T, Flockhart DA, Vance GH. Report of a new haplotype for ABCC2 gene; rs17222723 and rs8187718 in cis. J Mol Diagnostics 2015; 17:201-2015.

Soster EL, Tucker M, Escobar LF, Vance GH. Hydranencephaly in a newborn with a FLVCR2 mutation and prenatal cocaine exposure. Birth Defects Research Part A: Clinical and Molecular Teratology 2015; 103(1):45-50.

Wiens AL, Martin SE, Bertsch EC, Vance GH, Stohler RA, Cheng L, Badve S. Hattab EM. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma. Arch Pathol Lab Med 2014; 138(2): 175-182.  

Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane L, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G,  Hayes DF. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology-College of American Pathologists Clinical Practice Guideline Update.  Published ahead of print October 2013 as Arch Pathol Lab Med, doi:105858/arpa.2013-0953SA.  Print: Arch Pathol Lab Med 2014; 138 (2):241-256.

Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane L, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology-College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology 2013; 31:3997-4013.

Chakraborty S, Adams J, Nassari M. Vance GH. Therapy-related myeloid neoplasm with bone marrow involvement, myelosarcoma and t(8;16)(p11.2:p13.3) - a case report. Cancer Genetics 2014; 207:511-515.

Schneider BP, Gray RJ, Radovich M, Shen F, Vance GH, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenker TN, Nielsen KV, Muller S, Thor A, Sledge GW, Sparan JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with pacitaxel with and without bevacizumab; results from ECOG 2100 trial. Clinical Cancer Research, 2013; 19:1281-1289.

Hall AL, Drendel HM, Verbrugge JL, Reese AM, Griffith C, Weaver DD, Abernathy MP, Litton CG, Vance GH.  Positive cell-free DNA testing for trisomy 13 reveals confined placental mosaicism. Genetics in Medicine 2013; 15:729-732.

Machado C, Teo R, Warren SJP, Mousdicas N, Lacerda MA, Vance GH, Stohler R, Vianna R. Fluorescence in situ hybridization (FISH) as an aid for the diagnosis of graft versus host disease in two multivisceral organ transplant patients.  Am. J. Dermatopath 2013; 35(4): 496-502.

Peddibhotla S. Khalifa M, Probst F, Stein J, Harris LL, Kearney DL, Vance GH, Bull MJ, , Grange DK, Scharer GH, Kang SH, Stankiewicz P, Bacino CA, Cheung SW, Patel A. Expanding the Genotype- Phenotype correlation in subtelomeric 19p13.3 microdeletions using high resolution clinical chromosomal microarray analysis. Am J Med Genet Part A 2013; 9999:1-11 Online Pub med: Oct 2 doi:10.1002/ajmg.a.35886.